期刊
JOURNAL OF CLINICAL PATHOLOGY
卷 67, 期 9, 页码 751-757出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/jclinpath-2014-202467
关键词
-
类别
资金
- Roche Molecular Systems
- AstraZeneca
- Pfizer
- Cancer Research UK [18815] Funding Source: researchfish
- Cancer Research UK
- Versus Arthritis [18824] Funding Source: researchfish
Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of anti-epidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and additional KRAS mutations also predict for poor response to anti-EGFR therapy. The following document provides guidance on RAS (i.e., KRAS and NRAS) testing of CRC tissue in the setting of personalised medicine within the UK and particularly within the NHS. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such RAS testing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据